Takeda Pharmaceutical Wins Patent Infringement Case on ACTOS in US.Tokyo, Japan, Feb 24, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Takeda Pharmaceutical and its US subsidiary Takeda Pharmaceuticals North America jointly announced on February 22 that they have won a patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. case against Mylan, Watson and Ranbaxy. The US District Court for the Southern District of New York ruled on February 21 that Takeda's patent covering the active ingredient of ACTOS (pioglitazone HCI (Human Computer Interaction) Refers to the design and implementation of computer systems that people interact with. It includes desktop systems as well as embedded systems in all kinds of devices. ) is valid and enforceable. Accordingly, the US Food and Drug Administration cannot approve any generic version of ACTOS until 2011, when Takeda's patent expires. In addition, Takeda Pharmaceutical retains several patents regarding ACTOS and its use, which are valid until 2016. ACTOS is an insulin resistance reducer for type 2 diabetes type 2 diabetes n. See diabetes mellitus. . Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion